Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 601–700 of 1,002
Li, Y., Yang, C. H., Khan, M., Liu, S., Hedrick, J. L., Yang, Y. Y., & Ee, P. L. R. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.043 · Cited by 57
“A number of non-viral gene carriers such as cationic polymers [18], peptide [19] and lipid [20] have been introduced to hydrogels for gene transfection due to the low immunogenicity and high safety as compared to viral carriers [21,22].”
BackgroundOptimization of poly(amido amine)s as vectors for siRNA delivery
van der Aa, L. J., Vader, P., Storm, G., Schiffelers, R. M., & Engbersen, J. F. J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.030 · Cited by 57
Critical Length of PEG Grafts on lPEI/DNA Nanoparticles for Efficient in Vivo Delivery
Williford, J., Archang, M. M., Minn, I., Ren, Y., Wo, M., Vandermark, J., Fisher, P. B., Pomper, M. G., & Mao, H. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00551 · Cited by 57
Michel, T., Luft, D., Abraham, M.-K., Reinhardt, S., Salinas Medina, M. L., Kurz, J., Schaller, M., Avci-Adali, M., Schlensak, C., Peter, K., et al. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.07.013 · Cited by 49
“However, viral vectors have limitations, including carcinogenic and immunogenic properties,(14,15) difficult production,(16) and limited packaging capacity.(17,18) For non-viral approaches, DNA or RNA is frequently encapsulated with positively charged liposomes and polysomes to form lipoplexes or polyplexes, respectiv…”
BackgroundNonviral genome engineering of natural killer cells
Robbins, G. M., Wang, M., Pomeroy, E. J., & Moriarity, B. S. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02406-6 · Cited by 58
Salminen, M., Airenne, K. J., Rinnankoski, R., Reimari, J., Välilehto, O., Laakkonen, J. P., Suikkanen, S., Kukkonen, S. P., Ylä‐Herttuala, S., Kulomaa, M. S., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2720-2728.2005 · Cited by 57
“In recent years, a large number of vectors based on various viruses have been developed as gene transfer vehicles for use in gene therapy applications (21, 40, 44).”
BackgroundHakim, A. M., Guido, B., Narsineni, L., Chen, D.-W., & Földvári, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114781 · Cited by 56
Osaki, M., Okada, F., & Ochiya, T. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.122 · Cited by 56
Distribution of DNA-condensing protein complexes in the adenovirus core
Perez-Berna, A. J., Marion, S., Chichón, F. J., Fernández, J., Winkler, D. C., Carrascosa, J. L., Steven, A. C., Šiber, A., & Martín, C. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv187 · Cited by 56
“In medicine they are investigated as infective particles causing typically mild diseases, but also as vectors for vaccine and gene delivery and oncolysis (12).”
BackgroundMultifunctional Natural Polymer Nanoparticles as Antifibrotic Gene Carriers for CKD Therapy
Midgley, A. C., Wei, Y., Zhu, D., Gao, F., Yan, H., Khalique, A., Luo, W., Jiang, H., Liu, X., Guo, J., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019111160 · Cited by 56
Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy
Ruan, S., Huang, Y., He, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202200027 · Cited by 56
Advances in MicroRNAs: Implications for Gene Therapists
Marquez, R. T., & McCaffrey, A. P. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.147 · Cited by 56
“A significant hurdle to the application of gene replacement therapy is the development of transgene-specific immunity (Thomas et al ., 2003).”
The potential of nanomedicine therapies to treat neovascular disease in the retina
Farjo, K. M., & Ma, J. (2010) · Vascular Cell · doi:10.1186/2040-2384-2-21 · Cited by 56
“However, there are significant safety concerns regarding the use of rAAV for gene therapy, as human clinical trials with rAAV have lead to oncogenesis and fatal systemic inflammation [79,81-83].”
BackgroundNanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55
A Comprehensive Review on Recent Progress in Carbon Nanotubes for Biomedical Application
Shabnum, S. S., Ravichandran, S., Raj, C. K., Nivetha, P., & Benazir, K. (2025) · Environmental Quality Management · doi:10.1002/tqem.70040 · Cited by 55
Park, H., Lee, J., Kim, M.-J., Kang, T. J., Jeong, Y., Um, S. H., & Cho, S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.005 · Cited by 55
Manojkumar, K., Charan, K. T. P., Sivaramakrishna, A., Jha, P. C., Khedkar, V. M., Ramamoorthy, S., Jayaraman, G., & Vijayakrishna, K. (2015) · Biomacromolecules · doi:10.1021/bm5018029 · Cited by 55
Disulfide-functional poly(amido amine)s with tunable degradability for gene delivery
Elzes, M. R., Akeroyd, N., Engbersen, J. F. J., & Paulusse, J. M. J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.021 · Cited by 55
Harmon, B. T., Aly, A. E.-E., Padegimas, L., Sesenoglu‐Laird, O., Cooper, M. J., & Waszczak, B. L. (2014) · Gene Therapy · doi:10.1038/gt.2014.28 · Cited by 55
Xu, J., Lu, Y., Ding, F., Zhan, X., Zhu, M., & Wang, Z. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-9168-2 · Cited by 55
“early on, that they would be ideal targets for retrovirusmediated [27–29] transgene delivery strategies [16–18, 23].”
BackgroundGene-based antiangiogenic applications for corneal neovascularization
Liu, S., Romano, V., Steger, B., Kaye, S. B., Hamill, K. J., & Willoughby, C. E. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.10.006 · Cited by 56
Progress in the Development of Nucleic Acids Therapeutics for Cancer
Kalota, A., Shetzline, S. E., & Gewirtz, A. M. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.1.517 · Cited by 55
Peng, C., Cherng, J., Chiou, G., Chen, Y., Chien, C.-H., Kao, C.-L., Chang, Y.-L., Chien, Y., Chen, L., Liu, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.008 · Cited by 54
Delivering a disease-modifying treatment for Huntington's disease
Godinho, B. M. D. C., Malhotra, M., O’Driscoll, C. M., & Cryan, J. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.011 · Cited by 54
André, E. M., Passirani, C., Seijo, B., Sánchez, A., & Montero‐Menei, C. N. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.008 · Cited by 54
Synthesis of Multifunctional PAMAM–Aminoglycoside Conjugates with Enhanced Transfection Efficiency
Ghilardi, A., Pezzoli, D., Bellucci, M. C., Malloggi, C., Negri, A. L., Sganappa, A., Tedeschi, G., Candiani, G., & Volonterio, A. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4003635 · Cited by 54
miRNA-29b improves bone healing in mouse fracture model
Lee, W., Li, N., Lin, S., Wang, B., Lan, H. Y., & Li, G. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.04.014 · Cited by 54
Li, L., Li, X., Wu, Y., Song, L., Yang, X., He, T., Wang, N., Yang, S., Zeng, Y., Wu, Q., et al. (2017) · Theranostics · doi:10.7150/thno.17588 · Cited by 54
“Although some clinical trials reported promising outcomes with viral gene carriers, the fundamental drawbacks of severe immune/inflammatory reactions, recombination with wild-type viruses, limited DNA packaging capacity, and difficulty of vector production severely limit their application [14-18].”
BackgroundEngineering the niche for hair regeneration — A critical review
Nilforoushzadeh, M. A., Zare, M., Zarrintaj, P., Alizadeh, E., Taghiabadi, E., Heidari-Kharaji, M., Amirkhani, M. A., Saeb, M. R., & Mozafari, M. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.08.012 · Cited by 49
Advances on non-invasive physically triggered nucleic acid delivery from nanocarriers
Do, H. D., Couillaud, B. M., Doan, B., Corvis, Y., & Mignet, N. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.006 · Cited by 54
Mesenchymal stem cell-derived microvesicles mediate BMP2 gene delivery and enhance bone regeneration
Liang, Z., Luo, Y. G., & Lv, Y. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00422g · Cited by 54
High Throughput and Highly Controllable Methods for In Vitro Intracellular Delivery
Brooks, J. R., Minnick, G., Mukherjee, P., Jaberi, A., Chang, L., Espinosa, H. D., & Yang, R. (2020) · Small · doi:10.1002/smll.202004917 · Cited by 54
Serafini, M., Naldini, L., & Introna, M. (2004) · Virology · doi:10.1016/j.virol.2004.04.038 · Cited by 54
Zeng, S., Chen, Y., Zhou, F., Zhang, T., Fan, X., Chrzanowski, W., Gillies, M. C., & Zhu, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114965 · Cited by 53
Poly(β-amino esters): Procedures for Synthesis and Gene Delivery
Green, J. J., Zugates, G. T., Langer, R., & Anderson, D. G. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-59745-429-2_4 · Cited by 48
“, immunogenicity, reversion to the wild type), limited DNA carrying capacity, and production/quality control challenges (1,2).”
BackgroundHuman embryonic stem cell-derived vascular smooth muscle cells in therapeutic neovascularisation
Cheung, C., & Sinha, S. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.07.014 · Cited by 53
Darvishi, B., Farahmand, L., & Majidzadeh‐A, K. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.03.007 · Cited by 53
Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety
Teboul, L., Hérault, Y., Wells, S. E., Qasim, W., & Pavlovic, G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.015 · Cited by 53
“As with any other therapeutic agent, the delivery mode itself of GETs brings inherent safety risks: viruses can be associated with a high risk of gene disruption(82) or can cause problems of toxicity and immunogenicity.(83) Likewise, transfer of naked DNA to cells is known to activate an immune response.”
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 53
“A separate packaging constrict is used to aid in the replication of the modified viral genome in the packaging cells, in which the deleted genes encoding the viral replication as well as the viral capsid proteins are included in this constrict (Thomas et al., 2003).”
BackgroundMethodInfluentialPlasmid Engineering for Controlled and Sustained Gene Expression for Nonviral Gene Therapy
van Gaal, E. V. B., Hennink, W. E., Crommelin, D. J. A., & Mastrobattista, E. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0164-2 · Cited by 53
“Constructs from several viruses including EBV, BK virus (BKV), SV40, and bovine papilloma virus 1 (BPV-1) have been investigated as episomal expression vector candidates (30,106).”
BackgroundEfficient Gene Delivery and Multimodal Imaging by Lanthanide-Based Upconversion Nanoparticles
Wang, L., Liu, J., Dai, Y., Yang, Q., Zhang, Y., Yang, P., Cheng, Z., Lian, H., Li, C., Hou, Z., et al. (2014) · Langmuir · doi:10.1021/la503444g · Cited by 52
Functional Magnetic Nanoparticles for Non-Viral Gene Delivery and MR Imaging
Xing, R., Liu, G., Zhu, J., Hou, Y., & Chen, X. S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1205-2 · Cited by 53
Peng, J., Garcia, M. A., Choi, J., Zhao, L., Chen, K., Bernstein, J. R., Peyda, P., Hsiao, Y., Liu, K. W., Lin, W., et al. (2014) · ACS Nano · doi:10.1021/nn5003024 · Cited by 52
“tory responses, and potential insertion mutagenesis limit their clinical use.(5) By mi-”
BackgroundMultimodal Magnetic Nanoclusters for Gene Delivery, Directed Migration, and Tracking of Stem Cells
Park, J. S., Park, W., Park, S., Larson, A. C., Kim, D., & Park, K. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201700396 · Cited by 52
A summary on non-viral systems for gene delivery based on natural and synthetic polymers
Sarvari, R., Nouri, M., Agbolaghi, S., Roshangar, L., Sadrhaghighi, A., Seifalian, A. M., & Keyhanvar, P. (2020) · International Journal of Polymeric Materials · doi:10.1080/00914037.2020.1825081 · Cited by 52
“Despite the VVs advantages, the insertion mutation and other adverse impacts have been detected during their post-transfections([33]).”
BackgroundCurrent strategies employed in the manipulation of gene expression for clinical purposes
Tsai, H., Pietrobon, V., Peng, M., Wang, S., Zhao, L., Marincola, F. M., & Cai, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03747-3 · Cited by 53
Nonviral ocular gene therapy: assessment and future directions.
Conley, S. M., Cai, X., & Naash, M. I. (2008) · PubMed · Cited by 54
Wu, C., Yang, G., Bermúdez‐Humarán, L. G., Pang, Q., Zeng, Y., Wang, J., & Gao, X. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.09.010 · Cited by 52
Regulatable Gene Expression Systems for Gene Therapy
Vilaboa, N. E., & Voellmy, R. W. (2006) · Current Gene Therapy · doi:10.2174/156652306777934829 · Cited by 52
Cationic liposome–nucleic acid complexes: liquid crystal phases with applications in gene therapy
Safinya, C. R., Ewert, K. K., & Leal, C. (2011) · Liquid Crystals · doi:10.1080/02678292.2011.624364 · Cited by 52
Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems
Youngren-Ortiz, S. R., Gandhi, N. S., España‐Serrano, L., & Chougule, M. B. (2015) · KONA Powder and Particle Journal · doi:10.14356/kona.2016014 · Cited by 51
Neumann, A. J., Alini, M., Archer, C. W., & Stoddart, M. J. (2013) · Tissue Engineering Part A · doi:10.1089/ten.tea.2012.0411 · Cited by 51
“Viral vectors, on the other hand, are much more efficient, but their application raises safety concerns.(29,30) Adenoviral vectors, which do not integrate into the host genome, can be used as effective tools to provide a local, although transient, production of a bioactive factor.”
DNA compaction by azobenzene-containing surfactant
Zakrevskyy, Y., Kopyshev, A., Lomadze, N., Morozova, E., Lysyakova, L., Kasyanenko, N. A., & Santer, S. A. (2011) · Physical Review E · doi:10.1103/physreve.84.021909 · Cited by 51
Sun, L., Guo, R., Gao, H., Sarma, J. V., Zetoune, F. S., & Ward, P. A. (2009) · The FASEB Journal · doi:10.1096/fj.09-133694 · Cited by 51
“Several viral vectors have been used to induce RNAi silencing in cultured cells and in experimental animals, including lentivirus (47, 48), retrovirus (49), adenovirus (50–53), and adenovirus-associated viruses (54, 55).”
BackgroundCanonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Cheng, C., Saltzman, W. M., & Slack, F. J. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320290004 · Cited by 51
Lee, Y., Wu, H., Yeh, C., Kuan, C., Liao, H.-T., Hsu, H., Tsai, J.-C., Sun, J., & Wang, T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.09.008 · Cited by 51
Macrocycle-wrapped polyethylenimine for gene delivery with reduced cytotoxicity
Huang, Q., Li, S., Ding, Y., Yin, H., Wang, L., & Wang, R. (2018) · Biomaterials Science · doi:10.1039/c8bm00022k · Cited by 51
Multiparametric slice culture platform for the investigation of human cardiac tissue physiology
Qiao, Y., Dong, Q., Li, B., Obaid, S. N., Miccile, C., Yin, R. T., Talapatra, T., Lin, Z., Li, S., Li, Z., et al. (2018) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2018.06.001 · Cited by 51
Ma, Y., Zhao, W., Li, Y., Pan, Y., Wang, S., Zhu, Y., Kong, L., Guan, Z., Wang, J., Zhang, L., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.033 · Cited by 51
In-vitro and in-vivo difference in gene delivery by lithocholic acid-polyethyleneimine conjugate
Wang, J., Meng, F., Kim, B.-K., Ke, X., & Yeo, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119296 · Cited by 50
“Viral vectors are most widely used as the carrier of therapeutic genes in clinical studies; however, acute immunogenicity, low loading capacity, and difficulty in large-scale production remain their limitations [3, 4].”
BackgroundGraphene oxide as a 2D platform for complexation and intracellular delivery of siRNA
de Lázaro, I., Vranic, S., Marson, D., Rodrigues, A. F., Buggio, M., Esteban-Arranz, A., Mazza, M., Posocco, P., & Kostarelos, K. (2019) · Nanoscale · doi:10.1039/c9nr02301a · Cited by 51
Unal, O., Akkoç, Y., Koçak, M., Nalbat, E., Ekici, I. D., Acar, H. Y., & Gözüaçık, D. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00615-4 · Cited by 51
Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery
Dutta, K., Das, R., Medeiros, J., & Thayumanavan, S. (2021) · Biochemistry · doi:10.1021/acs.biochem.0c00860 · Cited by 51
Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
Chuang, S. T., Conklin, B., Stein, J. B., Pan, G., & Lee, K. (2022) · Nano Convergence · doi:10.1186/s40580-022-00310-0 · Cited by 51
García‐Calderó, H., Rodríguez-Vilarrupla, A., Gracia‐Sancho, J., Diví, M., Laviña, B., Bosch, J., & García‐Pagán, J. C. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.034 · Cited by 51
“Although it is a valuable research tool, the use of adenovirus-based gene therapies is highly controversial in humans [30].”
BackgroundNovel Liposomal Formulation for Targeted Gene Delivery
Rivest, V., Phivilay, A., Julien, C., Bélanger, S., Tremblay, C., Émond, V., & Calon, F. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9224-x · Cited by 53
“However, most of the available viral vectors are associated with major safety problems such as mutagenesis due to long-term integration into the genome (retrovirus or adeno-associated virus, AAV) or serious inflammatory responses (herpes simplex virus-1, HSV-1, or adenovirus, AV), making the translation into clinical…”
BackgroundInfluentialHigh, K. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01460.x · Cited by 51
de Azevedo, M. S. P., Karczewski, J., Lefèvre, F., Azevedo, V., Miyoshi, A., Wells, J. M., Langella, P., & Chatel, J. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-299 · Cited by 50
“Additionally, it was shown that some viral vectors have the capacity to randomly integrate their genetic material into the host genome causing insertional mutagenesis of a cellular oncogene, leading to tumour formation [10].”
BackgroundA novel cationic liposome formulation for efficient gene delivery via a pulmonary route
Li, P., Liu, D., Sun, X., Liu, C., Liu, Y., & Zhang, N. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/24/245104 · Cited by 50
Intracellular antibodies and cancer: New technologies offer therapeutic opportunities
Pérez-Martínez, D., Tanaka, T. U., & Rabbitts, T. H. (2010) · BioEssays · doi:10.1002/bies.201000009 · Cited by 50
“the advantage of long-lasting antibody fragment expression inside cells by stably integrating the expression cassette into the genome, but this may also cause problems such as activation of oncogenes and consequently inducing secondary cancers, as has been found in the X-SCID and CGD gene therapy trials [44, 45].”
Dehshahri, A., & Sadeghpour, H. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.05.006 · Cited by 51
Kao, C., & Papoutsakis, E. T. (2018) · Science Advances · doi:10.1126/sciadv.aau6762 · Cited by 50
Gold Nanoparticles as Targeted Delivery Systems and Theranostic Agents in Cancer Therapy
Mioc, A., Mioc, M., Ghiulai, R. M., Voicu, M., Racoviceanu, R., Trandafirescu, C. M., Dehelean, C. A., Coricovac, D. E., & Şoica, C. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190506123721 · Cited by 50
Dhas, N. L., Kudarha, R. R., Pandey, A. P., Nikam, A. N., Sharma, S., Singh, A. K., Garkal, A., Hariharan, K., Singh, A., Bangar, P., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.021 · Cited by 50
Patino, C. A., Pathak, N., Mukherjee, P., Park, S. H., Bao, G., & Espinosa, H. D. (2022) · Science Advances · doi:10.1126/sciadv.abn7637 · Cited by 50
“However, the immunogenic response to viral particles and the random integration of viral DNA in the host genome are remaining concerns ( 14 ) for use in therapeutics.”
BackgroundTumor vessel co-option: The past & the future
Cuypers, A., Truong, A.-C. K., Becker, L. M., Saavedra-García, P., & Carmeliet, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.965277 · Cited by 50
Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells
Hindriksen, S., Bramer, A. J., Truong, M. A., Vromans, M. J. M., Post, J. B., Verlaan-Klink, I., Snippert, H. J. G., Lens, S. M. A., & Hadders, M. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179514 · Cited by 50
“Again, a major drawback is the limited packaging capacity of AAV vectors [55].”
Lauterbach, H., Ried, C., Epstein, A. L., Marconi, P., & Brocker, T. (2005) · Journal of General Virology · doi:10.1099/vir.0.81104-0 · Cited by 50
“HSV-1-derived vectors, including replication-deficient and infectious single-cycle (DISC) vectors or amplicons, offer many advantages over other viral vectors for gene-therapeutic and vaccine approaches [reviewed by Thomas et al. (2003)].”
BackgroundNoncationic Material Design for Nucleic Acid Delivery
Jiang, Z., & Thayumanavan, S. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900206 · Cited by 49
Antoniou, V., Mourelatou, E. A., Galatou, E., Avgoustakis, K., & Hatziantoniou, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070868 · Cited by 49
“…by the immunogenicity of viral vectors; insertional mutagenesis, i.e., the random insertion of viral genetic material into the human genome, resulting in an undesired mutation; as well as more complex and costly production process [11], have led researchers to seek alternative gene carriers.”
BackgroundLarge-scale production of lipoplexes with long shelf-life
Clement, J., Kiefer, K., Kimpfler, A., Garidel, P., & Peschka‐Süss, R. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.06.001 · Cited by 49
Zhou, Y., Tang, Z., Shi, C., Shi, S., Qian, Z., & Zhou, S. (2012) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-012-4720-5 · Cited by 49
“Although viral vectors have been proven to possess high gene transfection efficiency, they have disadvantages such as immunogenicity, potential of insertional mutagenesis in the host genome, limited DNA delivery capacity and scale of production [6].”
BackgroundVirus-Vectored Influenza Virus Vaccines
Tripp, R. A., & Tompkins, S. M. (2014) · Viruses · doi:10.3390/v6083055 · Cited by 49
“The first trial was a gene therapy examination where high-dose intravenous delivery of an Ad vector resulted in the death of an 18-year-old male [42,43].”
BackgroundLiu, Y., Wang, Y., Zhang, C., Zhou, P., Liu, Y., An, T., Sun, D., Zhang, N., & Wang, Y. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am504203x · Cited by 49
Park, H., Tsutsumi, H., & Mihara, H. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.094 · Cited by 49
Monitoring intracellular degradation of exogenous DNA using diffusion properties
Sasaki, A., & Kinjo, M. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.013 · Cited by 49
“Nonviral vectors have advantages such as a low immune response and no risk of a disorder, which might be caused by native viral vector genome integration [1].”
BackgroundNano Delivers Big: Designing Molecular Missiles for Cancer Therapeutics
Patel, S., Bhirde, A. A., Rusling, J. F., Chen, X. S., Gutkind, J. S., & Patel, V. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3010034 · Cited by 49
“Historically, viral vectors wer e the preferred delivery mode, but preliminary clinic al studies triggered fatal inflammatory reactions i one patient and leukemogenesis in another, divertin g efforts into synthetic, less immunogenic vector systems able to be systemically administered [48].”
BackgroundDendron conjugation to graphene oxide using click chemistry for efficient gene delivery
Sarkar, K., Madras, G., & Chatterjee, K. (2015) · RSC Advances · doi:10.1039/c5ra07004j · Cited by 49
Layek, B., & Singh, J. (2013) · Biomacromolecules · doi:10.1021/bm401204n · Cited by 49
Tambe, P., Kumar, P., Karpe, Y. A., Paknikar, K. M., & Gajbhiye, V. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11024 · Cited by 49
Near‐Infrared Manipulation of Membrane Ion Channels via Upconversion Optogenetics
Wang, Z., Hu, M., Ai, X., Zhang, Z., & Xing, B. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800233 · Cited by 49
Sun, D., Sun, Z., Jiang, H., Vaidya, A. M., Xin, R., Ayat, N. R., Schilb, A. L., Qiao, P. L., Han, Z., Naderi, A., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00856 · Cited by 49
Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
Kamimura, K., Yokoo, T., Abé, H., & Terai, S. (2019) · Cancers · doi:10.3390/cancers11121865 · Cited by 49
“A virus-based gene delivery system represents a group of artificially made, replication-deficient viruses [104,105]; the most commonly used virus-based gene delivery systems are adeno-associated viral vectors [49,106], lentiviral vectors [105,107], adenoviral vectors [105,108], foamy viral vectors [109], herpes simple…”
MethodNanoparticle depots for controlled and sustained gene delivery
Li, Z., Ho, W., Bai, X., Li, F., Chen, Y.-J., Zhang, X., & Xu, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.021 · Cited by 49
“The aforementioned delivery vectors can be generally classified into categories of viral and non-viral vectors, each with their benefits and drawbacks [6,7].”
BackgroundRadmanesh, F., Abandansari, H. S., Ghanian, M. H., Pahlavan, S., Varzideh, F., Yakhkeshi, S., Alikhani, M., Moradi, S., Braun, T. W., & Baharvand, H. (2021) · Angiogenesis · doi:10.1007/s10456-021-09778-6 · Cited by 49
Dissen, G. A., Lomniczi, A., Neff, T. L., Hobbs, T. R., Kohama, S. G., Kroenke, C. D., Galimi, F., & Ojeda, S. R. (2009) · Methods · doi:10.1016/j.ymeth.2009.06.004 · Cited by 49
Gene delivery in salivary glands: From the bench to the clinic
Samuni, Y., & Baum, B. J. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.06.014 · Cited by 49
Gene delivery nanoparticles specific for human microvasculature and macrovasculature
Shmueli, R. B., Sunshine, J. C., Xu, Z., Duh, E. J., & Green, J. J. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.01.006 · Cited by 48
Muroski, M. E., Morgan, T. J., Levenson, C. W., & Strouse, G. F. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505190q · Cited by 48
Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer
Campani, V., Salzano, G., Lusa, S., & Rosa, G. D. (2016) · Nanomaterials · doi:10.3390/nano6070131 · Cited by 48
“Viral vectors, such as Lentivirus, Adenovirus, and Herpes Simplex virus, have been proposed for efficient delivery of ncRNA, although the toxicity and the possible immune response, as well as the high cost of the therapies, make difficult the large use of this strategy [10,11].”
Background
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.